SINOGENE
Changping
About SINOGENE
Sinogene uses a solution called somatic cell nuclear transfer for pet cloning. Sinogene believes that the advancement of breeding and genetics will be beneficial to animal genetic research. The company's team includes scientists, doctors, and veterinary specialists.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Sep 2024)
- Website: sinogene.com.cn
- Phone: +86 400-616-2206
Industries & Categories
Biotechnology, Genetics, Health Care, Pet
Canonical: https://fsome.com/organization/sinogene-53450 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.